Enthusiasm for PARP inhibitor combinations raises hopes that synthetic lethality and restored antitumor immunity, therapeutic strategies with great success in other cancers, can benefit patients with SCLC. The gene discussed is PARP1; the disease is small cell lung carcinoma.